arrow
S

Santosha A. Vardhana

Memorial Sloan Kettering Cancer Center
H指数:44
被引数:6,951

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis

CXCL9作为一种新型预后标志物,用于识别患有噬血细胞性淋巴组织细胞增多症的成人高风险群体。

Blood
IF23.1
2026-02-263
PRE
Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma—A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial

I期研究:Mogamulizumab联合Pembrolizumab治疗复发或难治性非霍奇金淋巴瘤患者——国家癌症研究所实验治疗临床研究网络(NCI-ETCTN)试验

Cancers
IF4.4
2026-01-170
OAAI
Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma

二十年单机构数据揭示复发/难治性伯基特淋巴瘤的罕见长期生存者

2026-01-011
OA
Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
2024-11-150
OA
Dual-Vector-Transduction with Single-Step Magnetic Selection (Zip-sort) Increases Transgenic Payloads to Enhance CAR T Cell Activity

双向量转导结合单步磁选(Zip-sort)可增加转基因载荷以增强CAR T细胞活性

BLOOD
IF23.1
2024-11-050
PRE
Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Pembrolizumab和Entinostat治疗复发/难治性霍奇金淋巴瘤的II期试验最终应答和生存结果

BLOOD
IF23.1
2024-11-051
PRE
Pembrolizumab for Front-Line Treatment of Extranodal NK/T-Cell Lymphoma

帕博利珠单抗一线治疗结外NK/T细胞淋巴瘤

BLOOD
IF23.1
2024-11-050
PRE
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

具有MYC,BCL2和/或BCL6重排的有限阶段高级别b细胞淋巴瘤: BCL2重排导致不良结果

2024-10-140
OAAI
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

Duvelisib联合romidepsin治疗复发/难治性T细胞淋巴瘤: 1b/2a期试验

2024-06-171
PRE
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
2024-05-160
OAAI
Retrospective characterization of nodal marginal zone lymphoma
2023-08-244
OAAI